Erasca, Inc. announced two clinical trial collaboration and supply agreements (CTCSAs) with Novartis for the MEK inhibitor trametinib (MEKINIST®). The agreements will support the clinical development of the pan-RAF inhibitor naporafenib in combination with trametinib for the treatment of patients with RAS Q61X solid tumors in the Phase 1b SEACRAFT-1 trial and in patients with previously treated NRAS-mutant (NRASm) unresectable or metastatic melanoma in the randomized, pivotal Phase 3 SEACRAFT-2 trial. Erasca is sponsoring the trials, and Novartis is supplying trametinib at no cost.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.15 USD | -1.38% | +2.87% | +0.94% |
05-08 | Erasca, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-03 | North American Morning Briefing : Powell Awaited -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.94% | 325M | |
+22.56% | 46.71B | |
-1.51% | 41.52B | |
+48.83% | 41.8B | |
-3.42% | 29.55B | |
+10.13% | 25.78B | |
-20.44% | 19.26B | |
+26.45% | 11.98B | |
-0.14% | 12.14B | |
-0.47% | 12.08B |
- Stock Market
- Equities
- ERAS Stock
- News Erasca, Inc.
- Erasca, Inc. Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials